00984nas a2200241   4500000000100000008004100001260001200042653001700054653003000071653001900101653001700120653001100137653001200148100001700160700001400177700001700191245007000208856005800278300001200336490000700348520037300355022001400728       2020                            d  c01/202010aAntidiabetic10aerythema nodosum leprosum10alepra reaction10apharmacology10astress10atargets1 aThangaraju P1 aVarthya S1 aVenkatesan S00aTarget/therapies for chronic recurrent erythema nodosum leprosum.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446680/  a222-2260 v523 a<p>A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies.</p>  a1998-3751